drugset / Trial / NCT00956982
PEG-IFN Plus Ribavirin Combination Therapy for Older Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) alpha-2b plus ribavirin (RBV) for older Japanese patients (≧65years old) infected with hepatitis C virus (HCV) compared with younger patients(\< 65 years old).
Timeline
- Start
- 2004-12
- Primary completion
- 2008-07
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Subject | Ribavirin | Small molecule | 600 mg | Oral |
| Subject | Ribavirin | Small molecule | 800 mg | Oral |
| Subject | Ribavirin | Small molecule | 1000 mg | Oral |